丝裂霉素C（MCC）治疗晚期软组织肉瘤：欧洲癌症研究与治疗组织软组织和骨肉瘤组的一项II期研究
Mitomycin C (MCC) in advanced soft tissue sarcoma: a phase II study of the EORTC Soft Tissue and Bone Sarcoma Group.
作者信息
van Oosterom A T, Santoro A, Bramwell V, Davy M, Mouridsen H T, Thomas D, Sylvester R
出版信息
Eur J Cancer Clin Oncol. 1985 Apr;21(4):459-61. doi: 10.1016/0277-5379(85)90037-9.
Mitomycin C at a dose of 12 mg/m2 i.v. q 3 weeks was administered to 34 patients with measurable progressive advanced soft tissue sarcomas. No objective response was observed although in one of the 12 patients with overall stabilisation of disease a partial response was reported in lung lesions. The side-effects observed in this group of patients were generally mild. On the basis of this result the application of mitomycin C in this disease cannot be recommended.
对34例可测量的进展期晚期软组织肉瘤患者，静脉注射丝裂霉素C，剂量为12mg/m²，每3周一次。尽管在12例疾病总体稳定的患者中有1例报告肺部病变出现部分缓解，但未观察到客观缓解。该组患者观察到的副作用一般较轻。基于这一结果，不推荐在该疾病中应用丝裂霉素C。
Zotero 插件